Release Details

Biogen would like to commend our collaboration partner, Eisai, on today's U.S. Food and Drug Administration approval of LEQEMBI^TM via the Accelerated Approval pathway. Additional details can be found in a news release announcing the approval. An additional news release from Eisai on patient safety is available on Eisai’s website.

A separate news release from Eisai on LEQEMBI pricing is also available via their website.  Eisai is solely responsible for setting LEQEMBI’s price.